Prescriber's Corner
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
Kirollos S. Hanna, PharmD, BCPS, BCOP
From Mayo Clinic College of Medicine & Science, Rochester, Minnesota
Author’s disclosure of conflict of interest is found at the end of this article.
Correspondence to: Kirollos S. Hanna, PharmD, BCPS, BCOP, 14500 99th Avenue N, Maple Grove, MN 55369. E-mail: kirollos11@gmail.com
J Adv Pract Oncol 2020;11(4):412–417 |
https://doi.org/10.6004/jadpro.2020.11.4.8 |
© 2020 Harborside™
ABSTRACT
The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, a Nectin-4–targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration for patients with advanced or metastatic UC following chemotherapy and immunotherapy. Approval of enfortumab vedotin was based on findings from the EV-201 trial, which demonstrated objective response rates of 44%. Patients treated with enfortumab vedotin should be monitored for specific toxicities, including peripheral neuropathy, rash, and hyperglycemia. In this article, the clinical implications of enfortumab vedotin for the treatment of advanced UC are reviewed.
For access to the full length article, please
sign in.
